Cannabinoids, such as cannabidiol (CBD) hold great therapeutic promise as shown by both established (epilepsy, sclerosis) and emerging (psychosis, anxiety, mood, and sleep disorders, addiction, pain etc.) science. However, currently available delivery formats for cannabinoid medicine as well as ongoing R&D face challenges with regard to API absorption and patient compliance. Firstly, formulating with CBD can be challenging due to its variable oral bioavailability. Stability, solubility, and mode of administration all play a role in the rate of absorption of CBD. The oral bioavailability of CBD has been shown to be very low in humans (6%), as a result of incomplete absorption in the gut and significant pre-systemic elimination in the liver. It is estimated that up to 75% of orally absorbed CBD is removed by hepatic metabolism. Bioavailability of the active is directly linked to its therapeutic efficacy and the dose required to achieve a response. It is therefore important to identify solutions to enhance the bioavailability of CBD and other cannabinoids. The currently preferred option of medicine manufacturers to overcome this hurdle is delivering CBD in an oil vehicle because CBD absorption is increased in the presence of fatty foods. And it has been a smart choice with the technologies we have had at hand. But that comes with its own challenges regarding patient convenience, patient compliance, and a proven high variability between patients. Consuming large volumes of oil to reach the prescribed dose is not pleasant or easy. When it comes to children or people with a difficulty swallowing, it is almost impossible. Addressing this will make a difference for patient acceptance. In this session we would like to share the learnings from a two-year technology assessment process whereby our formulation and application scientists examined more than 200 prototypes and tested in vitro and in vivo several technologies for improving the bioavailability of CBD while enabling patient-friendly formats such as orodispersible tablets, chewables, capsules, and other oral delivery formats with high API loading.